You are here

Investor Relations

Home

Jeffrey Leiden, Chairman, President and CEO

Date	Title and Summary
Toggle SummaryFeb 14, 2019	Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission -Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) through 8 weeks of tezacaftor/ivacaftor treatment- -Tezacaftor in combination with ivacaftor was generally well tolerated and safety data were consistent with previous General Business
Toggle SummaryFeb 5, 2019	Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results - Full-year 2018 CF product revenues of $3.04 billion , a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million - - Full-year 2018 GAAP operating income increased 415% to $635 million ; non-GAAP operating income increased 97% to $1.11 billion - - Financial
Toggle SummaryJan 28, 2019	Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene -KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients- BOSTON --(BUSINESS WIRE)--Jan. 28, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for General Business